Literature DB >> 23091284

Treatment with low-dose atorvastatin, losartan, and their combination increases expression of vasoactive-related genes in rat aortas.

Mojca Lunder1, Gorazd Drevenšek, Darko Černe, Janja Marc, Miodrag Janić, Mišo Šabovič.   

Abstract

Recently it has been shown that statins and angiotensin receptor blockers (ARBs) at low doses express beneficial pleiotropic vascular effects. We aimed to explore whether these drugs at low doses induce the expression of vasoactive-related genes. Sixty adult Wistar rats were treated with low-dose atorvastatin (2 mg/kg), low-dose losartan (5 mg/kg), their combination or saline daily for 4, 6, or 8 weeks. Expression of the vasoactive-related genes endothelin receptor type A (EDNRA), endothelial nitric oxide synthase 3 (NOS3), inducible nitric oxide synthase 2 (NOS2), and angiotensin II receptor type 1 (AGTRL1a) was measured in isolated thoracic aortas. Expression of EDNRA gradually decreased, the lowest values being obtained after 8 weeks (low-dose atorvastatin, losartan [1.6- and 1-7-fold vs controls, respectively; both P < .05], and the combination [2.3-fold vs control, P < .001]). The highest values of NOS3 were obtained after 6 weeks (low-dose atorvastatin, losartan, and their combination, 3.1-fold, P < .01; 3.4-fold, P < .001; and 3.6-fold, P < .001 vs controls, respectively) and then declined after 8 weeks. The combination was more effective in inducing total NOS3 expression when compared to the separate drugs (1.4-fold; P < .05). Importantly, expression of NOS3 was associated with increased plasma NO levels and positively correlated with thoracic aorta relaxation. No changes in expression of NOS2 and AGTRL1a were observed. We showed that low-dose atorvastatin or losartan and especially their combination increases the expression of NOS3 and decreases the expression of EDNRA. These findings are valuable in explaining the effectiveness of the "low-dose pharmacological approach" for improvement in arterial function.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23091284     DOI: 10.1177/1074248412463966

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol Ther        ISSN: 1074-2484            Impact factor:   2.457


  5 in total

1.  Long-term improvement of arterial wall characteristics in patients with diabetes mellitus type 1 using cyclic, intermittent treatment with a low-dose fluvastatin and valsartan combination.

Authors:  Vedran Savić; Miodrag Janić; Mojca Lunder; Karin Kanc; Andrej Janež; Barbara Eržen; Mišo Šabovič
Journal:  Exp Ther Med       Date:  2015-07-07       Impact factor: 2.447

2.  A Combination of Low Doses of Fluvastatin and Valsartan Decreases Arterial Stiffness in Patients After Myocardial Infarction: A Pilot Study.

Authors:  Jurij Hanžel; Žiga Piletič; Martina Turk; Barbara Eržen; Mišo Šabovič
Journal:  Curr Ther Res Clin Exp       Date:  2015-06-06

Review 3.  A low-dose combination of fluvastatin and valsartan: a new "drug" and a new approach for decreasing the arterial age.

Authors:  Miodrag Janić; Mojca Lunder; Mišo Šabovič
Journal:  Biomed Res Int       Date:  2015-03-03       Impact factor: 3.411

Review 4.  Macrophage Heterogeneity and Plasticity: Impact of Macrophage Biomarkers on Atherosclerosis.

Authors:  Joselyn Rojas; Juan Salazar; María Sofía Martínez; Jim Palmar; Jordan Bautista; Mervin Chávez-Castillo; Alexis Gómez; Valmore Bermúdez
Journal:  Scientifica (Cairo)       Date:  2015-09-27

Review 5.  Angiotensin receptor blockers & endothelial dysfunction: Possible correlation & therapeutic implications.

Authors:  Miroslav Radenkovic; Marko Stojanović; Ivana Milićević Nešić; Milica Prostran
Journal:  Indian J Med Res       Date:  2016-08       Impact factor: 2.375

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.